CN114478773A - Cxcr4结合分子 - Google Patents

Cxcr4结合分子 Download PDF

Info

Publication number
CN114478773A
CN114478773A CN202210051480.9A CN202210051480A CN114478773A CN 114478773 A CN114478773 A CN 114478773A CN 202210051480 A CN202210051480 A CN 202210051480A CN 114478773 A CN114478773 A CN 114478773A
Authority
CN
China
Prior art keywords
seq
cxcr4
polypeptide
binding
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202210051480.9A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·弗利
安德鲁·颇乌
凯瑟琳·格里菲斯
萨曼莎·科博
卡特丽娜·维杜卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adalta Ltd
Original Assignee
Adalta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015900054A external-priority patent/AU2015900054A0/en
Application filed by Adalta Ltd filed Critical Adalta Ltd
Publication of CN114478773A publication Critical patent/CN114478773A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
CN202210051480.9A 2015-01-09 2016-01-08 Cxcr4结合分子 Withdrawn CN114478773A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2015900054A AU2015900054A0 (en) 2015-01-09 CXCR4 binding molecules
AU2015900054 2015-01-09
PCT/AU2016/050005 WO2016109872A1 (en) 2015-01-09 2016-01-08 Cxcr4 binding molecules
CN201680010938.9A CN107427574B (zh) 2015-01-09 2016-01-08 Cxcr4结合分子

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680010938.9A Division CN107427574B (zh) 2015-01-09 2016-01-08 Cxcr4结合分子

Publications (1)

Publication Number Publication Date
CN114478773A true CN114478773A (zh) 2022-05-13

Family

ID=56355354

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680010938.9A Active CN107427574B (zh) 2015-01-09 2016-01-08 Cxcr4结合分子
CN202210051480.9A Withdrawn CN114478773A (zh) 2015-01-09 2016-01-08 Cxcr4结合分子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680010938.9A Active CN107427574B (zh) 2015-01-09 2016-01-08 Cxcr4结合分子

Country Status (12)

Country Link
US (2) US10538596B2 (enExample)
EP (2) EP4112077A1 (enExample)
JP (3) JP6863897B2 (enExample)
CN (2) CN107427574B (enExample)
AU (3) AU2016206191B2 (enExample)
CA (1) CA2973317A1 (enExample)
DK (1) DK3242685T3 (enExample)
ES (1) ES2924394T3 (enExample)
HR (1) HRP20220860T1 (enExample)
LT (1) LT3242685T (enExample)
SG (2) SG10202111844VA (enExample)
WO (1) WO2016109872A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10538596B2 (en) * 2015-01-09 2020-01-21 Adalta Limited CXCR4 binding molecules and methods of use thereof
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018084712A1 (en) 2016-11-07 2018-05-11 Crossbeta Biosciences B.V. Novel amyloid beta oligomer specific binding molecule
EP3568160A1 (en) * 2017-01-16 2019-11-20 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Improved multi tyrosine kinase inhibitor therapy
CN111741752A (zh) * 2017-12-19 2020-10-02 Gpcr治疗公司 Gpcr异聚体抑制剂及其用途
CN113661240B (zh) * 2019-04-02 2024-11-05 伊莱利利公司 选择和检测结合肽的方法
CA3139912A1 (en) * 2019-05-17 2020-11-26 Gpcr Therapeutics, Inc. Gpcr heteromer inhibitors and uses thereof
JP7365674B2 (ja) * 2019-08-29 2023-10-20 国立大学法人 長崎大学 アスペルギローマモデル非ヒト動物
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
EP4118117A1 (en) * 2020-03-13 2023-01-18 Julius-Maximilians-Universität Würzburg Affinity matured and humanized binding domains targeting ror2
US20250297020A1 (en) * 2021-11-23 2025-09-25 Adalta Limited Rank-l binding molecules
CN114533884A (zh) * 2022-04-20 2022-05-27 澳门大学 一种联合治疗癌症的药物及s100a9-cxcl12信号抑制剂的应用
WO2025010469A1 (en) * 2023-07-07 2025-01-16 Adalta Limited Linking receptor occupancy to efficacy of cxcr4 antagonists

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118629A1 (en) * 2004-06-02 2005-12-15 Diatech Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
CN103897058A (zh) * 2006-10-02 2014-07-02 梅达雷克斯有限责任公司 结合cxcr4的人类抗体及其用途
CN104039320A (zh) * 2011-11-09 2014-09-10 百时美施贵宝公司 血液恶性肿瘤用抗-cxcr4抗体的治疗

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475A (en) 1846-04-25 Henry johnson
US4439A (en) 1846-04-04 Improvement in cleansing fish-oils
US196A (en) 1837-05-15 Machine for mowing and heaping grain
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5206154A (en) 1985-01-28 1993-04-27 Xoma Corporation Method of producing cecropins by microbiological techniques
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5215896A (en) 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
SE8804074D0 (sv) 1988-11-10 1988-11-10 Pharmacia Ab Sensorenhet och dess anvaendning i biosensorsystem
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0656952B1 (en) 1992-08-21 2003-03-05 The University Of British Columbia Cationic peptides and method for production
US5648244A (en) 1993-09-27 1997-07-15 President And Fellows Of Harvard College Production, purification, cleavage and use of fusion peptides
US5485277A (en) 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
US6037145A (en) 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
US5567301A (en) 1995-03-01 1996-10-22 Illinois Institute Of Technology Antibody covalently bound film immunobiosensor
US5972639A (en) 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
DE19818790A1 (de) 1998-04-27 1999-10-28 Affina Immuntechnik Gmbh Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung
US6489447B1 (en) 1998-05-06 2002-12-03 Genentech, Inc. Protein purification
AU5220099A (en) 1998-07-31 2000-02-21 Pierce Chemical Company Fusion products containing insoluble proteinaceous tag
US6190908B1 (en) 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
DK1187928T3 (da) 1999-06-30 2007-10-08 Evotec Ag Viruslignende partikler, fremstilling og anvendelse ved screening samt ved funktionel genomics
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2406873A1 (en) 2000-04-25 2001-11-01 Chemicon International, Inc. Cell proliferation assay
AU2002220577A1 (en) 2000-09-28 2002-04-08 Affina Immuntechnik Gmbh Circulatory device for separating substances in bodily fluids, especially blood,and the use of said device
DE60331226D1 (de) 2002-05-24 2010-03-25 Medtronic Inc Verfahren und dna-konstrukte zur produktion von polypeptiden mit hoher ausbeute
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
WO2005108415A2 (en) * 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
US7671069B2 (en) 2006-03-30 2010-03-02 Chemocentryx, Inc. Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
EP2078037A4 (en) 2006-11-10 2010-01-27 Dimerix Bioscience Pty Ltd HETERODIMERS / OLIGOMERS OF THE RECEPTOR FOR THE THYROTROPIN RELEASING HORMONE OF THE OREXIN RECEPTOR
WO2008109154A1 (en) 2007-03-08 2008-09-12 Altiris Therapeutics, Inc. Chemokine receptor modulators
JP5785089B2 (ja) 2008-11-04 2015-09-24 ケモセントリックス，インコーポレイティド Ｃｘｃｒ７の調節因子
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
AU2014226650A1 (en) * 2013-03-08 2015-10-01 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor
US10538596B2 (en) * 2015-01-09 2020-01-21 Adalta Limited CXCR4 binding molecules and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118629A1 (en) * 2004-06-02 2005-12-15 Diatech Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
CN103897058A (zh) * 2006-10-02 2014-07-02 梅达雷克斯有限责任公司 结合cxcr4的人类抗体及其用途
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
CN104039320A (zh) * 2011-11-09 2014-09-10 百时美施贵宝公司 血液恶性肿瘤用抗-cxcr4抗体的治疗

Also Published As

Publication number Publication date
JP7212009B2 (ja) 2023-01-24
CA2973317A1 (en) 2016-07-14
AU2016206191A1 (en) 2016-12-15
US20180072816A1 (en) 2018-03-15
ES2924394T3 (es) 2022-10-06
AU2019203511A1 (en) 2019-06-06
AU2017254863A1 (en) 2017-11-16
CN107427574A (zh) 2017-12-01
DK3242685T3 (da) 2022-07-25
EP3242685A1 (en) 2017-11-15
SG11201705583XA (en) 2017-08-30
AU2016206191A9 (en) 2017-01-19
JP6863897B2 (ja) 2021-04-21
US11142588B2 (en) 2021-10-12
JP2020182479A (ja) 2020-11-12
EP4112077A1 (en) 2023-01-04
JP2023015277A (ja) 2023-01-31
LT3242685T (lt) 2022-08-25
JP2018504112A (ja) 2018-02-15
SG10202111844VA (en) 2021-12-30
HRP20220860T1 (hr) 2022-10-14
EP3242685B1 (en) 2022-05-04
US20200231708A1 (en) 2020-07-23
US10538596B2 (en) 2020-01-21
WO2016109872A1 (en) 2016-07-14
EP3242685A4 (en) 2018-07-11
AU2019203511B2 (en) 2021-08-12
CN107427574B (zh) 2022-02-08
AU2016206191B2 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
JP7212009B2 (ja) Ｃｘｃｒ４結合分子
US11827712B2 (en) IL13Rα2 binding agents and use thereof
US20240025961A1 (en) CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
WO2018199318A1 (ja) 抗ｇｐｃ－１抗体
CN103501799A (zh) Wnt组合物及其使用方法
CN116323655A (zh) 一种SIRPα-Fc融合蛋白
KR20250067121A (ko) Cnx 항원-결합 분자
EP3273991B1 (en) Anti-cd89 cytotoxic complex
CN111378040A (zh) 检测多种恶性肿瘤细胞的抗体及其应用
CN121263440A (en) Recombinant CD2 binding proteins and uses thereof
WO2024251742A1 (en) Recombinant cd2 binding proteins and their use
HK1245288B (en) Car t-cells recognizing cancer-specific il 13r-alpha2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066087

Country of ref document: HK

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20220513